5 High Growth Pharma Stocks that are Profitable

2. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Q/Q Sales Growth: 725%

Number of Hedge Fund Holders in Q3 2022: 13

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biotechnology firm that is developing products for diseases such as cardiovascular problems, arthritis, and skin issues. It is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is finally on an upward trajectory, as its third quarter of 2022 revenues stood at $92 million, accounting for a 725% annual growth. These revenues were also greater than the firm’s net sales for the first nine months of 2021. 13 of the 920 hedge funds part of Insider Monkey’s Q3 2022 survey of 920 hedge funds had invested in the firm.

Julian Baker and Felix Baker’s Baker Bros. Advisors is Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s largest shareholder. It owns 2.7 million shares that are worth $41 million.

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)